Novartis (NVS)

[biopharm]

Novartis been researching PS Phosphatidylserine targeting ?

Drug: MBG453
MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).

David Epstein bring Jay Bradner and Glenn Dranoff over from Dana Farber to further pursue PS Targeting combinations ?

Novartis Glenn Dranoff been researching PS Targeting and Novartis requires that expertise yesterday, though will Novartis secure all rights? One hell of a week coming up to find out

https://www.nibr.com/stories/discovery/new-recruit-has-big-dreams-cancer-immunotherapy

Dana Farber is where Troy Luster went (also had collaborations with Evotec)

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129100057

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=102461358

Quote:
Of note, immediately following the anti-PS presentation, the discussion of the three preceding presentations, (abstracts 3003-3005), is led by none other than Dr. Glenn Dranoff himself, well-known and well-published Harvard immunologist, who recently has been studying the therapeutic anti-tumor effects achieved by blocking PS-mediated signaling.

Dranoff's 2008 paper published in the journal Clinical Cancer Research, titled ”Capitalizing on the Immunogenicity of Dying Tumor Cells”, should be "required reading" for anyone interested in how exposed PS is exploited by tumors to elude the cells of the immune system. In the paper, he speaks very broadly about the role of exposed PS in the apoptotic process common to all multicellular organisms, and he outlines experiments in which autologous tumor cells combined with PS-blocking yielded some very impressive experimental anti-tumor results.
3-15-08 CCR:

http://clincancerres.aacrjournals.org/cgi/content/full/14/6/1603

“Anti-PS, ASCO’09, and Glenn Dranoff” - Anti-PS blog, 5-8-09…
http://anti-ps.blogspot.com
http://anti-ps.blogspot.com/2009/05/anti-ps-asco-and-glenn-dranoff-interim.html

Interim data from a phase II clinical trial evaluating anti-PS in advanced breast cancer patients is slated for an oral presentation at the annual ASCO conference this year, (abstract #3005 [6-1-09 10:30am]).

Of note, immediately following the anti-PS presentation, the discussion of the three preceding presentations, (abstracts 3003-3005), is led by none other than Dr. Glenn Dranoff himself, well-known and well-published Harvard immunologist, who recently has been studying the therapeutic anti-tumor effects achieved by blocking PS-mediated signaling.

Dranoff's 2008 paper published in the journal Clinical Cancer Research, titled ”Capitalizing on the Immunogenicity of Dying Tumor Cells”, should be "required reading" for anyone interested in how exposed PS is exploited by tumors to elude the cells of the immune system. In the paper, he speaks very broadly about the role of exposed PS in the apoptotic process common to all multicellular organisms, and he outlines experiments in which autologous tumor cells combined with PS-blocking yielded some very impressive experimental anti-tumor results.
3-15-08 CCR: http://clincancerres.aacrjournals.org/cgi/content/full/14/6/1603

Also worth reading is Dranoff's recent WIPO patent application, in which he discusses tumor vaccines utilizing autologous tumor cells altered to express GM-CSF, combined with PS signaling blockers - including anti-PS antibodies.
http://tinyurl.com/qhtk9r

= = = = = = = =
Dr. Glenn Dranoff profile: http://tinyurl.com/rbfar6
…Associate Professor of Medicine, Harvard Medical School